File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/adhm.202001853
- Scopus: eid_2-s2.0-85103867688
- PMID: 33661553
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Combinatory Delivery of Etoposide and siCD47 in a Lipid Polymer Hybrid Delays Lung Tumor Growth in an Experimental Melanoma Lung Metastatic Model
Title | Combinatory Delivery of Etoposide and siCD47 in a Lipid Polymer Hybrid Delays Lung Tumor Growth in an Experimental Melanoma Lung Metastatic Model |
---|---|
Authors | |
Keywords | CD47 chemotherapy immunotherapy macrophages |
Issue Date | 2021 |
Citation | Advanced Healthcare Materials, 2021, v. 10, n. 7, article no. 2001853 How to Cite? |
Abstract | This study investigated the feasibility of lipid polymer hybrid nanoparticles (LPH) as a platform for the combinatorial delivery of small interfering RNA (siRNA) and etoposide (Eto). Different Eto loaded LPH formulations (LPH Eto) are prepared. The optimized cationic LPH Etowith a particle size of 109.66 ± 5.17 nm and Eto entrapment efficiency (EE %) of 80.33 ± 2.55 is used to incorporate siRNA targeting CD47 (siCD47), a do not eat me marker on the surface of cancer cells. The siRNA-encapsulating LPH (LPH siNEG-Eto) has a particle size of 115.9 ± 4.11 nm and siRNA EE % of 63.54 ± 4.36 %. LPHs improved the cellular uptake of siRNA in a dose- and concentration-dependent manner. Enhanced cytotoxicity (3.8-fold higher than Eto solution) and high siRNA transfection efficiency (≈50 %) are obtained. An in vivo biodistribution study showed a preferential uptake of the nanosystem into lung, liver, and spleen. In an experimental pseudo-metastatic B16F10 lung tumor model, a superior therapeutic outcome can be observed in mice treated with combinatory therapy. Immunological studies revealed elevated CD4+, CD8+ cells, and macrophages in the lung following combinatory treatment. The study suggests the potential of the current system for combinatory chemotherapy and immunotherapy for the treatment of lung cancer or lung metastasis. |
Persistent Identifier | http://hdl.handle.net/10722/349553 |
ISSN | 2023 Impact Factor: 10.0 2023 SCImago Journal Rankings: 2.337 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abdel-Bar, Hend Mohamed | - |
dc.contributor.author | Walters, Adam A. | - |
dc.contributor.author | Wang, Julie Tzu Wen | - |
dc.contributor.author | Al-Jamal, Khuloud T. | - |
dc.date.accessioned | 2024-10-17T06:59:18Z | - |
dc.date.available | 2024-10-17T06:59:18Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Advanced Healthcare Materials, 2021, v. 10, n. 7, article no. 2001853 | - |
dc.identifier.issn | 2192-2640 | - |
dc.identifier.uri | http://hdl.handle.net/10722/349553 | - |
dc.description.abstract | This study investigated the feasibility of lipid polymer hybrid nanoparticles (LPH) as a platform for the combinatorial delivery of small interfering RNA (siRNA) and etoposide (Eto). Different Eto loaded LPH formulations (LPH Eto) are prepared. The optimized cationic LPH Etowith a particle size of 109.66 ± 5.17 nm and Eto entrapment efficiency (EE %) of 80.33 ± 2.55 is used to incorporate siRNA targeting CD47 (siCD47), a do not eat me marker on the surface of cancer cells. The siRNA-encapsulating LPH (LPH siNEG-Eto) has a particle size of 115.9 ± 4.11 nm and siRNA EE % of 63.54 ± 4.36 %. LPHs improved the cellular uptake of siRNA in a dose- and concentration-dependent manner. Enhanced cytotoxicity (3.8-fold higher than Eto solution) and high siRNA transfection efficiency (≈50 %) are obtained. An in vivo biodistribution study showed a preferential uptake of the nanosystem into lung, liver, and spleen. In an experimental pseudo-metastatic B16F10 lung tumor model, a superior therapeutic outcome can be observed in mice treated with combinatory therapy. Immunological studies revealed elevated CD4+, CD8+ cells, and macrophages in the lung following combinatory treatment. The study suggests the potential of the current system for combinatory chemotherapy and immunotherapy for the treatment of lung cancer or lung metastasis. | - |
dc.language | eng | - |
dc.relation.ispartof | Advanced Healthcare Materials | - |
dc.subject | CD47 | - |
dc.subject | chemotherapy | - |
dc.subject | immunotherapy | - |
dc.subject | macrophages | - |
dc.title | Combinatory Delivery of Etoposide and siCD47 in a Lipid Polymer Hybrid Delays Lung Tumor Growth in an Experimental Melanoma Lung Metastatic Model | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1002/adhm.202001853 | - |
dc.identifier.pmid | 33661553 | - |
dc.identifier.scopus | eid_2-s2.0-85103867688 | - |
dc.identifier.volume | 10 | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | article no. 2001853 | - |
dc.identifier.epage | article no. 2001853 | - |
dc.identifier.eissn | 2192-2659 | - |